Symbols / RVPH Stock $0.90 +1.25% Reviva Pharmaceuticals Holdings, Inc.
RVPH (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Ratings
Current target
$0.90
Low
$1.00
High
$140.00
Mean
$58.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-08 | down | Maxim Group | Buy → Hold | — |
| 2026-03-31 | main | Roth Capital | Buy → Buy | $1 |
| 2026-03-30 | main | Alliance Global Partners | Buy → Buy | $30 |
| 2026-03-05 | down | D. Boral Capital | Buy → Hold | — |
| 2026-01-05 | main | Chardan Capital | Buy → Buy | $2 |
| 2025-12-23 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-12-23 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-11-19 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-10-28 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-09-29 | init | Chardan Capital | — → Buy | $2 |
| 2025-09-19 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-09-15 | main | Benchmark | Speculative Buy → Speculative Buy | $7 |
| 2025-08-18 | reit | Roth Capital | Buy → Buy | $3 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-08-15 | main | Maxim Group | Buy → Buy | $2 |
| 2025-06-27 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-06-03 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-05-20 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-04-24 | main | D. Boral Capital | Buy → Buy | $8 |
- Reviva CEO to discuss brilaroxazine milestones in April 27 chat - Stock Titan hu, 23 Apr 2026 12
- Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split - Yahoo Finance Wed, 25 Mar 2026 07
- Reviva Pharmaceuticals shares tumble after $9M public offering priced - MSN Sun, 26 Apr 2026 17
- RVPH Should I Buy - Intellectia AI hu, 05 Mar 2026 10
- Why Did RVPH Stock Crash 50% Today? - Stocktwits ue, 23 Dec 2025 08
- What's Behind The Drop In Reviva Pharmaceuticals Stock? - Benzinga hu, 19 Mar 2026 07
- Another schizophrenia trial stands between Reviva and an FDA filing - Stock Titan Mon, 30 Mar 2026 07
- Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026 - Yahoo Finance Sun, 11 Jan 2026 08
- Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00 - MSN Sat, 25 Apr 2026 01
- $23M on hand, patent push: Reviva lays out 2026 drug roadmap - Stock Titan Wed, 15 Apr 2026 07
- Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans - Yahoo Finance ue, 21 Apr 2026 02
- $10M raise backs Reviva's Phase 3 schizophrenia drug trial - Stock Titan Wed, 18 Mar 2026 07
- RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2 - Yahoo Finance Wed, 01 Apr 2026 07
- Reviva says $10M raise funds schizophrenia trial into Q1 2027 - Stock Titan Mon, 23 Mar 2026 07
- Reviva (NASDAQ: RVPH) CFO granted 40,925 stock options under 2020 plan - Stock Titan Fri, 20 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
20.20
-34.41%
|
30.80
-22.04%
|
39.50
+39.94%
|
28.23
|
| Research And Development |
|
11.71
-48.89%
|
22.91
-27.09%
|
31.42
+37.38%
|
22.87
|
| Selling General And Administration |
|
8.49
+7.60%
|
7.89
-2.38%
|
8.08
+50.85%
|
5.36
|
| General And Administrative Expense |
|
8.49
+7.60%
|
7.89
-2.38%
|
8.08
+50.85%
|
5.36
|
| Other Gand A |
|
8.49
+7.60%
|
7.89
-2.38%
|
8.08
+50.85%
|
5.36
|
| Total Expenses |
|
20.20
-34.41%
|
30.80
-22.04%
|
39.50
+39.94%
|
28.23
|
| Operating Income |
|
-20.20
+34.41%
|
-30.80
+22.04%
|
-39.50
-39.94%
|
-28.23
|
| Total Operating Income As Reported |
|
-20.20
+34.41%
|
-30.80
+22.04%
|
-39.50
-39.94%
|
-28.23
|
| EBITDA |
|
-19.83
+33.63%
|
-29.88
+23.79%
|
-39.21
-38.90%
|
-28.23
|
| Normalized EBITDA |
|
-19.92
+34.89%
|
-30.60
+21.48%
|
-38.97
-39.01%
|
-28.03
|
| Reconciled Depreciation |
|
—
|
—
|
—
|
—
|
| EBIT |
|
-19.83
+33.63%
|
-29.88
+23.79%
|
-39.21
-38.90%
|
-28.23
|
| Total Unusual Items |
|
0.09
-87.60%
|
0.72
+400.00%
|
-0.24
-22.86%
|
-0.19
|
| Total Unusual Items Excluding Goodwill |
|
0.09
-87.60%
|
0.72
+400.00%
|
-0.24
-22.86%
|
-0.19
|
| Net Income |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Pretax Income |
|
-19.85
+33.62%
|
-29.90
+23.81%
|
-39.24
-38.96%
|
-28.24
|
| Net Non Operating Interest Income Expense |
|
0.30
-13.10%
|
0.34
-5.98%
|
0.36
+99.50%
|
0.18
|
| Interest Expense Non Operating |
|
0.01
-27.55%
|
0.02
-45.15%
|
0.03
|
—
|
| Net Interest Income |
|
0.30
-13.10%
|
0.34
-5.98%
|
0.36
+99.50%
|
0.18
|
| Interest Expense |
|
0.01
-27.55%
|
0.02
-45.15%
|
0.03
|
—
|
| Interest Income Non Operating |
|
0.31
-13.84%
|
0.36
-9.30%
|
0.40
+117.95%
|
0.18
|
| Interest Income |
|
0.31
-13.84%
|
0.36
-9.30%
|
0.40
+117.95%
|
0.18
|
| Other Income Expense |
|
0.06
-89.93%
|
0.56
+630.52%
|
-0.10
+46.10%
|
-0.19
|
| Other Non Operating Income Expenses |
|
-0.03
+79.52%
|
-0.16
-219.84%
|
0.13
|
—
|
| Gain On Sale Of Security |
|
0.09
-87.60%
|
0.72
+400.00%
|
-0.24
-22.86%
|
-0.19
|
| Tax Provision |
|
0.02
-3.20%
|
0.02
+15.13%
|
0.02
-18.42%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.02
-87.60%
|
0.15
+400.00%
|
-0.05
-22.86%
|
-0.04
|
| Net Income Including Noncontrolling Interests |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Net Income From Continuing Operation Net Minority Interest |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Net Income From Continuing And Discontinued Operation |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Net Income Continuous Operations |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Normalized Income |
|
-19.94
+34.61%
|
-30.49
+21.98%
|
-39.07
-39.01%
|
-28.11
|
| Net Income Common Stockholders |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Diluted EPS |
|
—
|
-18.00
+45.45%
|
-33.00
-32.00%
|
-25.00
|
| Basic EPS |
|
—
|
-18.00
+45.45%
|
-33.00
-32.00%
|
-25.00
|
| Basic Average Shares |
|
—
|
1.66
+39.29%
|
1.19
+21.94%
|
0.98
|
| Diluted Average Shares |
|
—
|
1.66
+39.29%
|
1.19
+21.94%
|
0.98
|
| Diluted NI Availto Com Stockholders |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.18
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
15.92
+2.71%
|
15.50
-34.59%
|
23.70
+25.24%
|
18.92
|
| Current Assets |
|
15.10
+2.86%
|
14.68
-38.05%
|
23.70
+25.24%
|
18.92
|
| Cash Cash Equivalents And Short Term Investments |
|
14.44
+7.14%
|
13.48
-42.33%
|
23.37
+26.18%
|
18.52
|
| Cash And Cash Equivalents |
|
14.44
+7.14%
|
13.48
-42.33%
|
23.37
+26.18%
|
18.52
|
| Cash Equivalents |
|
13.23
+8.40%
|
12.20
-45.06%
|
22.21
|
—
|
| Cash Financial |
|
1.21
-4.92%
|
1.27
+10.13%
|
1.16
|
—
|
| Prepaid Assets |
|
0.00
-100.00%
|
0.54
+590.47%
|
0.08
-80.61%
|
0.40
|
| Other Current Assets |
|
0.66
-0.26%
|
0.67
+161.72%
|
0.25
-36.94%
|
0.40
|
| Total Non Current Assets |
|
0.82
+0.00%
|
0.82
|
0.00
|
0.00
|
| Non Current Prepaid Assets |
|
0.82
+0.00%
|
0.82
|
0.00
|
—
|
| Total Liabilities Net Minority Interest |
|
7.28
-50.47%
|
14.69
-18.30%
|
17.98
+70.78%
|
10.53
|
| Current Liabilities |
|
7.28
-50.17%
|
14.60
-14.98%
|
17.18
+72.41%
|
9.96
|
| Payables And Accrued Expenses |
|
6.38
-52.75%
|
13.51
-16.70%
|
16.22
+72.56%
|
9.40
|
| Payables |
|
3.01
-52.11%
|
6.28
+63.24%
|
3.85
+9.34%
|
3.52
|
| Accounts Payable |
|
3.01
-52.11%
|
6.28
+63.24%
|
3.85
+9.34%
|
3.52
|
| Current Accrued Expenses |
|
3.37
-53.30%
|
7.22
-41.59%
|
12.37
+110.43%
|
5.88
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.49
-23.55%
|
0.64
-33.70%
|
0.96
+69.77%
|
0.56
|
| Current Debt And Capital Lease Obligation |
|
0.41
-11.19%
|
0.46
|
—
|
—
|
| Current Debt |
|
0.41
-11.19%
|
0.46
|
—
|
—
|
| Other Current Borrowings |
|
0.41
-11.19%
|
0.46
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.09
-88.97%
|
0.81
+42.16%
|
0.57
|
| Stockholders Equity |
|
8.65
+964.23%
|
0.81
-85.79%
|
5.72
-31.87%
|
8.39
|
| Common Stock Equity |
|
8.65
+964.23%
|
0.81
-85.79%
|
5.72
-31.87%
|
8.39
|
| Capital Stock |
|
0.01
+150.21%
|
0.00
+66.83%
|
0.00
+36.53%
|
0.00
|
| Common Stock |
|
0.01
+150.21%
|
0.00
+66.83%
|
0.00
+36.53%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
5.87
+152.17%
|
2.33
+66.84%
|
1.40
+36.54%
|
1.02
|
| Ordinary Shares Number |
|
5.87
+152.17%
|
2.33
+66.84%
|
1.40
+36.54%
|
1.02
|
| Additional Paid In Capital |
|
192.77
+16.78%
|
165.08
+17.86%
|
140.07
+35.35%
|
103.49
|
| Retained Earnings |
|
-184.14
-12.09%
|
-164.27
-22.27%
|
-134.35
-41.29%
|
-95.09
|
| Total Equity Gross Minority Interest |
|
8.65
+964.23%
|
0.81
-85.79%
|
5.72
-31.87%
|
8.39
|
| Total Capitalization |
|
8.65
+964.23%
|
0.81
-85.79%
|
5.72
-31.87%
|
8.39
|
| Working Capital |
|
7.83
+9462.46%
|
0.08
-98.75%
|
6.53
-27.19%
|
8.96
|
| Invested Capital |
|
9.05
+612.55%
|
1.27
-77.78%
|
5.72
-31.87%
|
8.39
|
| Total Debt |
|
0.41
-11.19%
|
0.46
|
—
|
—
|
| Net Tangible Assets |
|
8.65
+964.23%
|
0.81
-85.79%
|
5.72
-31.87%
|
8.39
|
| Tangible Book Value |
|
8.65
+964.23%
|
0.81
-85.79%
|
5.72
-31.87%
|
8.39
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
0.09
-88.97%
|
0.81
+42.16%
|
0.57
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-24.59
+26.68%
|
-33.54
-18.43%
|
-28.32
-49.39%
|
-18.96
|
| Cash Flow From Continuing Operating Activities |
|
-24.59
+26.68%
|
-33.54
-18.43%
|
-28.32
-49.39%
|
-18.96
|
| Net Income From Continuing Operations |
|
-19.86
+33.60%
|
-29.92
+23.79%
|
-39.26
-38.92%
|
-28.26
|
| Depreciation Amortization Depletion |
|
—
|
—
|
—
|
—
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
—
|
—
|
—
|
—
|
| Other Non Cash Items |
|
—
|
—
|
—
|
—
|
| Stock Based Compensation |
|
2.23
+36.65%
|
1.63
-52.24%
|
3.41
+1831.34%
|
0.18
|
| Operating Gains Losses |
|
-0.09
+87.60%
|
-0.72
-400.00%
|
0.24
+22.86%
|
0.19
|
| Gain Loss On Investment Securities |
|
-0.09
+87.60%
|
-0.72
-400.00%
|
0.24
+22.86%
|
0.19
|
| Change In Working Capital |
|
-6.87
-51.36%
|
-4.54
-162.30%
|
7.28
-18.43%
|
8.93
|
| Change In Prepaid Assets |
|
0.54
+132.02%
|
-1.69
-2489.47%
|
0.07
-94.60%
|
1.31
|
| Change In Payables And Accrued Expense |
|
-7.41
-160.58%
|
-2.84
-139.43%
|
7.21
-5.31%
|
7.62
|
| Change In Accrued Expense |
|
-4.00
+22.04%
|
-5.14
-174.59%
|
6.88
+49.45%
|
4.61
|
| Change In Payable |
|
-3.41
-248.73%
|
2.29
+596.75%
|
0.33
-89.08%
|
3.01
|
| Change In Account Payable |
|
-3.41
-248.73%
|
2.29
+596.75%
|
0.33
-89.08%
|
3.01
|
| Financing Cash Flow |
|
25.56
+8.05%
|
23.65
-28.70%
|
33.17
+325.69%
|
7.79
|
| Cash Flow From Continuing Financing Activities |
|
25.56
+8.05%
|
23.65
-28.70%
|
33.17
+325.69%
|
7.79
|
| Net Issuance Payments Of Debt |
|
-0.05
-111.19%
|
0.46
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.41
-58.35%
|
0.98
+46.35%
|
0.67
|
0.00
|
| Repayment Of Debt |
|
-0.46
+11.68%
|
-0.52
+22.28%
|
-0.67
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Issuance |
|
0.41
-58.35%
|
0.98
+46.35%
|
0.67
|
0.00
|
| Short Term Debt Payments |
|
-0.46
+11.68%
|
-0.52
+22.28%
|
-0.67
|
0.00
|
| Net Short Term Debt Issuance |
|
-0.05
-111.19%
|
0.46
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
18.63
-19.67%
|
23.19
-15.64%
|
27.49
+253.69%
|
7.77
|
| Proceeds From Stock Option Exercised |
|
6.98
+4681822.82%
|
0.00
-100.00%
|
5.68
+29836.99%
|
0.02
|
| Changes In Cash |
|
0.96
+109.73%
|
-9.89
-304.04%
|
4.85
+143.41%
|
-11.17
|
| Beginning Cash Position |
|
13.48
-42.33%
|
23.37
+26.18%
|
18.52
-37.62%
|
29.69
|
| End Cash Position |
|
14.44
+7.14%
|
13.48
-42.33%
|
23.37
+26.18%
|
18.52
|
| Free Cash Flow |
|
-24.59
+26.68%
|
-33.54
-18.43%
|
-28.32
-49.39%
|
-18.96
|
| Interest Paid Supplemental Data |
|
0.01
-27.55%
|
0.02
-39.60%
|
0.03
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
-1.40%
|
0.00
-82.70%
|
0.02
+19.84%
|
0.02
|
| Change In Interest Payable |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
18.63
-19.67%
|
23.19
-15.64%
|
27.49
+253.69%
|
7.77
|
| Issuance Of Capital Stock |
|
18.63
-19.67%
|
23.19
-15.64%
|
27.49
+253.69%
|
7.77
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-15 View
- 8-K2026-03-30 View
- 10-K2026-03-30 View
- 42026-03-20 View
- 42026-03-20 View
- 8-K2026-03-19 View
- 8-K2026-03-05 View
- 8-K2026-01-23 View
- 8-K2025-12-23 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 8-K2025-11-13 View
- 10-Q2025-11-13 View
- 8-K2025-10-17 View
- 8-K2025-09-26 View
- 8-K2025-09-19 View
- 8-K2025-08-14 View
- 10-Q2025-08-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|